Percutaneous transvalvular micro-axial flow pump in infarct related cardiogenic shock: Results of the DANGER-shock Trial
Reported from ACC.24
Mirvat Alasnag interviews Jacob Eifer Møller about the results of the DANGER-shock Trial which he presented at the ACC.24 in Atlanta.
Results show that the implantation of microaxial flow pump post-heart attack significantly boosts survival in patients with STEMI-related cardiogenic shock, though with increased complications. The trial's positive findings indicate potential routine use in severe cases, with benefits persisting beyond 30 days, albeit with notable risks.
Authors
No comments yet!